Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.

Journal of thrombosis and thrombolysis

Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, Mann KG.
PMID: 10603519
J Thromb Thrombolysis. 1994;1(1):101-107. doi: 10.1007/BF01062003.

Background: Myocardial ischemia at rest is typically associated with atherosclerotic coronary artery disease, atherommous plaque rupture, and intracoronary thrombosis. In areas of advanced disease and vascular injury, the extent of thrombus is influenced largely by a delicate balance of...

Cite
Becker RC, Tracy RP, Bovill EG, et al. Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. J Thromb Thrombolysis. 1994;1(1):101-107doi: 10.1007/BF01062003.
Becker, R. C., Tracy, R. P., Bovill, E. G., Corrao, J. M., Baker, S., Ball, S. P., & Mann, K. G. (1994). Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. Journal of thrombosis and thrombolysis, 1(1), 101-107. https://doi.org/10.1007/BF01062003
Becker, et al. "Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest." Journal of thrombosis and thrombolysis vol. 1,1 (1994): 101-107. doi: https://doi.org/10.1007/BF01062003
Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, Mann KG. Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. J Thromb Thrombolysis. 1994;1(1):101-107. doi: 10.1007/BF01062003. PMID: 10603519.
Copy Download .nbib Format: NLM
Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative.

Research and practice in thrombosis and haemostasis

Cushman M, Larson JC, Rosendaal FR, Heckbert SR, Curb JD, Phillips LS, Baird AE, Eaton CB, Stafford RS.
PMID: 30046733
Res Pract Thromb Haemost. 2018 Apr 17;2(2):310-319. doi: 10.1002/rth2.12100. eCollection 2018 Apr.

BACKGROUND: Oral menopausal hormone therapy causes venous thrombosis but whether biomarkers of thrombosis risk can identify women at risk is unknown.METHODS: We completed a nested case control study in the two Women's Health Initiative hormone trials; 27 347 women...

Cite
Cushman M, Larson JC, Rosendaal FR, et al. Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative. Res Pract Thromb Haemost. 2018;2(2):310-319doi: 10.1002/rth2.12100.
Cushman, M., Larson, J. C., Rosendaal, F. R., Heckbert, S. R., Curb, J. D., Phillips, L. S., Baird, A. E., Eaton, C. B., & Stafford, R. S. (2018). Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative. Research and practice in thrombosis and haemostasis, 2(2), 310-319. https://doi.org/10.1002/rth2.12100
Cushman, Mary, et al. "Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative." Research and practice in thrombosis and haemostasis vol. 2,2 (2018): 310-319. doi: https://doi.org/10.1002/rth2.12100
Cushman M, Larson JC, Rosendaal FR, Heckbert SR, Curb JD, Phillips LS, Baird AE, Eaton CB, Stafford RS. Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative. Res Pract Thromb Haemost. 2018 Apr 17;2(2):310-319. doi: 10.1002/rth2.12100. eCollection 2018 Apr. PMID: 30046733; PMCID: PMC5974918.
Copy Download .nbib Format: NLM
Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin.

Journal of thrombosis and thrombolysis

Andreotti F, Lefroy DC, Sciahbasi A, Crake T, Maseri A, Marco E, Davies GJ.
PMID: 10751796
J Thromb Thrombolysis. 1998 Sep;6(2):141-145. doi: 10.1023/A:1008805823198.

Thromboembolic complications are reported to occur in up to 0.5-2% of left cardiac catheterizations and angiographies. Activation of the hemostatic system may contribute to their onset. To prevent platelet and thrombin activity during catheterization, aspirin or systemic heparin are...

Cite
Andreotti F, Lefroy DC, Sciahbasi A, et al. Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. J Thromb Thrombolysis. 1998;6(2):141-145doi: 10.1023/A:1008805823198.
Andreotti, F., Lefroy, D. C., Sciahbasi, A., Crake, T., Maseri, A., Marco, E., & Davies, G. J. (1998). Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. Journal of thrombosis and thrombolysis, 6(2), 141-145. https://doi.org/10.1023/A:1008805823198
Andreotti, et al. "Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin." Journal of thrombosis and thrombolysis vol. 6,2 (1998): 141-145. doi: https://doi.org/10.1023/A:1008805823198
Andreotti F, Lefroy DC, Sciahbasi A, Crake T, Maseri A, Marco E, Davies GJ. Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. J Thromb Thrombolysis. 1998 Sep;6(2):141-145. doi: 10.1023/A:1008805823198. PMID: 10751796.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.

European journal of drug metabolism and pharmacokinetics

Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J.
PMID: 34893967
Eur J Drug Metab Pharmacokinet. 2021 Dec 11; doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11.

Desmoteplase is a bat (Desmodus rotundus) saliva-derived fibrinolytic enzyme resembling a urokinase and tissue plasminogen activator. It is highly dependent on fibrin and has some neuroprotective attributes. Intravenous administration of desmoteplase is safe and well tolerated in healthy subjects....

Cite
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, et al. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. Eur J Drug Metab Pharmacokinet. 2021;doi: 10.1007/s13318-021-00743-8.
Piechowski-Jozwiak, B., Abidi, E., El Nekidy, W. S., & Bogousslavsky, J. (2021). Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. European journal of drug metabolism and pharmacokinetics, . https://doi.org/10.1007/s13318-021-00743-8
Piechowski-Jozwiak, Bartlomiej, et al. "Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase." European journal of drug metabolism and pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s13318-021-00743-8
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. Eur J Drug Metab Pharmacokinet. 2021 Dec 11; doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11. PMID: 34893967.
Copy Download .nbib Format: NLM
Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia.

Pediatric blood & cancer

Carmona R, Kizilocak H, Marquez-Casas E, Vasquez S, Ji L, Ko RH, Young G, Jaffray J.
PMID: 34963026
Pediatr Blood Cancer. 2021 Dec 28;e29522. doi: 10.1002/pbc.29522. Epub 2021 Dec 28.

BACKGROUND: Venous thromboembolism (VTE) is a known complication for children with acute lymphoblastic leukemia (ALL). The aim of this study was to identify laboratory biomarkers that predict which children with ALL are at risk for VTE during induction chemotherapy.MATERIALS...

Cite
Carmona R, Kizilocak H, Marquez-Casas E, et al. Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;e29522doi: 10.1002/pbc.29522.
Carmona, R., Kizilocak, H., Marquez-Casas, E., Vasquez, S., Ji, L., Ko, R. H., Young, G., & Jaffray, J. (2021). Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatric blood & cancer, e29522. https://doi.org/10.1002/pbc.29522
Carmona, Roxana, et al. "Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia." Pediatric blood & cancer vol. (2021): e29522. doi: https://doi.org/10.1002/pbc.29522
Carmona R, Kizilocak H, Marquez-Casas E, Vasquez S, Ji L, Ko RH, Young G, Jaffray J. Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 Dec 28;e29522. doi: 10.1002/pbc.29522. Epub 2021 Dec 28. PMID: 34963026.
Copy Download .nbib Format: NLM
Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023).

Journal of thrombosis and thrombolysis

Zeymer U, Mateblowski M, Neuhaus KL.
PMID: 10767116
J Thromb Thrombolysis. 1998 Jul;5(3):203-207. doi: 10.1023/A:1008839824942.

Thrombin contributes to the pathogenesis of acute myocardial infarction and reocclusion after thrombolysis. Thrombolytic therapy is known to induce a paradoxic increase in thrombin generation. Specific thrombin inhibition enhances thrombolytic therapy in experimental models. The aim of this study...

Cite
Zeymer U, Mateblowski M, Neuhaus KL. Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023). J Thromb Thrombolysis. 1998;5(3):203-207doi: 10.1023/A:1008839824942.
Zeymer, U., Mateblowski, M., & Neuhaus, K. L. (1998). Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023). Journal of thrombosis and thrombolysis, 5(3), 203-207. https://doi.org/10.1023/A:1008839824942
Zeymer, et al. "Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023)." Journal of thrombosis and thrombolysis vol. 5,3 (1998): 203-207. doi: https://doi.org/10.1023/A:1008839824942
Zeymer U, Mateblowski M, Neuhaus KL. Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023). J Thromb Thrombolysis. 1998 Jul;5(3):203-207. doi: 10.1023/A:1008839824942. PMID: 10767116.
Copy Download .nbib Format: NLM
Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation.

Scientific reports

Cohen CT, Turner NA, Moake JL.
PMID: 34750441
Sci Rep. 2021 Nov 08;11(1):21852. doi: 10.1038/s41598-021-01360-w.

In a previous study, we reported that human endothelial cells (ECs) express and produce their own coagulation factors (F) that can activate cell surface FX without the additions of external proteins or phospholipids. We now describe experiments that detail...

Cite
Cohen CT, Turner NA, Moake JL. Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Sci Rep. 2021;11(1):21852doi: 10.1038/s41598-021-01360-w.
Cohen, C. T., Turner, N. A., & Moake, J. L. (2021). Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Scientific reports, 11(1), 21852. https://doi.org/10.1038/s41598-021-01360-w
Cohen, Clay T, et al. "Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation." Scientific reports vol. 11,1 (2021): 21852. doi: https://doi.org/10.1038/s41598-021-01360-w
Cohen CT, Turner NA, Moake JL. Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Sci Rep. 2021 Nov 08;11(1):21852. doi: 10.1038/s41598-021-01360-w. PMID: 34750441; PMCID: PMC8575941.
Copy Download .nbib Format: NLM
Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation.

Scientific reports

Cohen CT, Turner NA, Moake JL.
PMID: 34750441
Sci Rep. 2021 Nov 08;11(1):21852. doi: 10.1038/s41598-021-01360-w.

In a previous study, we reported that human endothelial cells (ECs) express and produce their own coagulation factors (F) that can activate cell surface FX without the additions of external proteins or phospholipids. We now describe experiments that detail...

Cite
Cohen CT, Turner NA, Moake JL. Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Sci Rep. 2021;11(1):21852doi: 10.1038/s41598-021-01360-w.
Cohen, C. T., Turner, N. A., & Moake, J. L. (2021). Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Scientific reports, 11(1), 21852. https://doi.org/10.1038/s41598-021-01360-w
Cohen, Clay T, et al. "Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation." Scientific reports vol. 11,1 (2021): 21852. doi: https://doi.org/10.1038/s41598-021-01360-w
Cohen CT, Turner NA, Moake JL. Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation. Sci Rep. 2021 Nov 08;11(1):21852. doi: 10.1038/s41598-021-01360-w. PMID: 34750441; PMCID: PMC8575941.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.

European journal of drug metabolism and pharmacokinetics

Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J.
PMID: 34893967
Eur J Drug Metab Pharmacokinet. 2021 Dec 11; doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11.

Desmoteplase is a bat (Desmodus rotundus) saliva-derived fibrinolytic enzyme resembling a urokinase and tissue plasminogen activator. It is highly dependent on fibrin and has some neuroprotective attributes. Intravenous administration of desmoteplase is safe and well tolerated in healthy subjects....

Cite
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, et al. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. Eur J Drug Metab Pharmacokinet. 2021;doi: 10.1007/s13318-021-00743-8.
Piechowski-Jozwiak, B., Abidi, E., El Nekidy, W. S., & Bogousslavsky, J. (2021). Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. European journal of drug metabolism and pharmacokinetics, . https://doi.org/10.1007/s13318-021-00743-8
Piechowski-Jozwiak, Bartlomiej, et al. "Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase." European journal of drug metabolism and pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s13318-021-00743-8
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. Eur J Drug Metab Pharmacokinet. 2021 Dec 11; doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11. PMID: 34893967; PMCID: PMC8664670.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries